Novo Nordisk sues Eli Lilly under Lanham Act over 2-year-old GLP-1 ad claims

This lawsuit places false advertising law at the center of the GLP-1 arms race. Novo’s Lanham Act challenge asks a federal court to decide whether a competitor’s new product approval renders a previously defensible head-to-head claim misleading—a test that could reshape standards for real-time accuracy in pharmaceutical marketing. The outcome may guide how strictly courts demand ongoing monitoring of competitor data in dynamic drug sectors.

Novo Nordisk has escalated the fiercely competitive battle over the world’s most lucrative drug class by filing a federal lawsuit against Eli Lilly, accusing its rival of consumer deception in advertising for GLP-1 weight-loss therapies. The suit, lodged July 21, 2026, in the U.S. District Court for the District of New Jersey, marks a rare direct legal confrontation between the two dominant players in the exploding obesity and diabetes market. At stake is not just market share in a segment projected to exceed $100 billion within the decade, but also the credibility of clinical messaging that shapes prescribing habits and patient demand.

“

Novo Nordisk has escalated the fiercely competitive battle over the world’s most lucrative drug class by filing a federal lawsuit against Eli Lilly, accusing its rival of consumer deception in advertising for GLP-1 weight-loss therapies.

The core allegation centers on Eli Lilly’s nationwide promotional campaigns for Zepbound, which Novo says rely on “outdated” clinical comparisons. Specifically, Lilly’s ads highlight a head-to-head trial pitting the highest dose of Zepbound against lower doses of Novo’s Wegovy. Novo contends that since the March 2026 approval of a high-dose Wegovy formulation delivering weight loss far more comparable to Zepbound, those ads now mislead consumers by suggesting Lilly’s drug is categorically superior. Novo’s group general counsel, John Kuckelman, stated that the comparisons leave consumers with the “inevitable conclusion that Lilly’s medicines are superior to Novo’s, and that’s not accurate.”

The legal action follows an April 2026 cease-and-desist letter from Novo demanding Lilly remove or correct the ads, which Lilly refused. Novo is now seeking a permanent injunction to pull the offending campaigns, a mandatory order to issue corrective advertising, and unspecified monetary damages. It has also signaled it will seek a preliminary injunction within days to halt the ads while the litigation proceeds. Lilly, for its part, issued a statement asserting it “stands firmly behind our advertising,” arguing that the only robust head-to-head study remains the one it cites and that the ads are “truthful, transparent, and grounded in the most direct scientific evidence available.”

Beneath the legal sparring lies a high-stakes commercial reality. The GLP-1 class—dominated by Novo’s semaglutide (Ozempic, Wegovy) and Lilly’s tirzepatide (Mounjaro, Zepbound)—has reshaped modern medicine and Wall Street expectations. Both companies’ market capitalizations have soared, and each is racing to expand indications, improve dosing convenience, and lock in prescriber loyalty. Advertising is a critical tool to influence patient conversations with doctors, especially as direct-to-consumer campaigns flood television, social media, and search platforms. A finding that Lilly’s ads are deceptive could not only force costly adjustments but also taint its brand trust among physicians and consumers who increasingly rely on comparative efficacy claims.

The lawsuit also invites broader regulatory scrutiny. While the FDA oversees drug labeling and promotional materials, civil actions under the Lanham Act provide a mechanism for competitors to police each other’s marketing. Novo’s choice to litigate rather than rely solely on FDA enforcement signals a belief that the agency’s process is too slow or toothless to address rapid changes in the advertising landscape. If the court finds that the ads are literally false or misleading by omission, it could set a precedent on how companies must update comparative claims when new data emerges—particularly when those new data come from a competitor’s product approvals rather than new head-to-head trials.